Valo Health Merges With Montai Therapeutics
The combined company will operate under the Valo brand, with Valo CEO Brian Alexander continuing to lead.
Updated on Nov. 11, 2026 in Healthcare

Valo Health and Montai Therapeutics announced a merger, and the combined company will operate under the Valo brand. The specific terms of the merger have not been disclosed.
Why it matters
The deal consolidates two AI-focused drug developers whose pipelines span oncology, neurodegenerative and cardiovascular disease, along with inflammatory and dermatologic conditions. It brings together partnerships that Valo and Montai have already built with major pharmaceutical companies.
Valo Health launched in 2020 with almost $100 million in financing, and Montai Therapeutics was founded in 2022 with a $50 million investment. The financial terms of the merger remain undisclosed, leaving the combined company's valuation unknown.
The players
Valo Health
An AI-driven drug development company launched by Flagship Pioneering in 2020 to speed up therapeutic discovery in oncology, neurodegenerative and cardiovascular disease.
Montai Therapeutics
A drug developer founded in 2022 with an initial $50 million investment, known for its MTAI-1025 NRF2 agonist program and collaborations with NVIDIA and Pfizer.
Merck KGaA
A German pharmaceutical and life sciences company that entered a Parkinson's disease collaboration with Valo Health worth up to $3 billion.
Flagship Pioneering
A venture-building firm that launched Valo Health and has backed Montai Therapeutics through its CEO-partner network.
The details
The merged company will advance a pipeline led by MTAI-1025, an oral NRF2 agonist in Phase 1 for ulcerative colitis, alongside an oral STAT6 inhibitor for atopic dermatitis. Valo's existing partnerships, including a Parkinson's disease collaboration with Germany's Merck KGaA worth up to $3 billion, and Montai's work with Pfizer on lung cancer candidates, will continue.
Timeline
2020: Valo Health launched by Flagship Pioneering with almost $100 million in financing.
2022: Montai Therapeutics founded with a $50 million initial investment.
2024: Montai Therapeutics teamed up with Pfizer through Flagship to identify non-small cell lung cancer candidates.
2025: Valo linked up with Merck KGaA on a Parkinson's disease-focused deal worth up to $3 billion.
November 11, 2026: Valo and Montai announced the merger.
Industry Dynamics
The merger follows the venture-building model Flagship Pioneering used to launch Valo Health in 2020, consolidating related drug developers under one AI-focused platform. It reflects a broader push in healthcare to pair machine learning with drug discovery across multiple disease areas.
Any drugs advanced by the merged company remain in early development, so no treatment changes are available to patients yet. Patients with the conditions targeted, including ulcerative colitis, atopic dermatitis, and Parkinson's disease, should continue current care while the pipeline progresses.
The takeaway
Combining AI-driven drug discovery platforms may consolidate expertise and partnerships, but the financial terms and near-term clinical milestones of the merged pipeline remain to be seen. Readers should watch for disclosed deal terms and trial updates.
Further reading
For more on the sector, explore Healthcare coverage on Wisevoter.
Source note: This article includes information reported by FierceBiotech - free daily biotech briefing.



